Medical Treatment of Heart Failure: Problems in Dilated Cardiomyopathy

  • J. N. Cohn
Conference paper


The management of dilated cardiomyopathy involves two distinct goals [1]. One is to relieve symptoms and improve the quality of life of patients who suffer congestive heart failure as a consequence of a dilated, remodeled ventricle. The second, equally important, goal is to delay the progressive remodeling process which appears to eventuate in premature death. It is this latter goal that has been the subject of most recent large-scale trials on the management of heart failure.


Chronic Heart Failure Dilate Cardiomyopathy Brain Natriuretic Peptide Atrial Natriuretic Peptide Left Ventricular Remodel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cohn JN (1996) Drug therapy: the management of chronic heart failure. N Engl J Med 335:490–498PubMedCrossRefGoogle Scholar
  2. 2.
    Levine TB, Francis GS, Goldsmith SR, Simon A, Cohn JN (1982) Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49:1659–1666PubMedCrossRefGoogle Scholar
  3. 3.
    Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R (1992) Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85:504–509PubMedCrossRefGoogle Scholar
  4. 4.
    Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN (1983) Increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol 1:1385–1390PubMedCrossRefGoogle Scholar
  5. 5.
    Burnett JC Jr, Kao PC, Hu DC et al. (1986) Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231:1145–1147PubMedCrossRefGoogle Scholar
  6. 6.
    Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr (1993) Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 341:1105–1109PubMedCrossRefGoogle Scholar
  7. 7.
    Sumida H, Yasue H, Yoshimura M, Okumura K, Ogawa H, Kugiyama K, Matsuyama K, Kikuta K, Morita E, Nakao K (1995) Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 25:1105–1110PubMedCrossRefGoogle Scholar
  8. 8.
    Hosoda K, Nakao K, Mukoyama M, Saito Y, Jougasaki M, Shirakami G, Suga S, Ogawa Y, Yasue H, Imura H (1991) Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension 17:1152–1155PubMedCrossRefGoogle Scholar
  9. 9.
    The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325:293–302CrossRefGoogle Scholar
  10. 10.
    Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B (1986) Effect of vasodilator therapy on mortality in chronic congestive hearth failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 314:1547–1552Google Scholar
  11. 11.
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355PubMedCrossRefGoogle Scholar
  12. 12.
    McDonald KM, Carlyle PF, Matthews J, Hauer K, Elbers T, Hunter D, Cohn JN (1990) Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Amer Physicians 103:229–235Google Scholar
  13. 13.
    McDonald KM, Francis GS, Matthews J, Hunter D, Cohn JN (1993) Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. J Am Coll Cardiol 21:514–522PubMedCrossRefGoogle Scholar
  14. 14.
    McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN (1994) Angiotensinconverting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol 24:1762–1768PubMedCrossRefGoogle Scholar
  15. 15.
    The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685–691CrossRefGoogle Scholar
  16. 16.
    Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic betaadrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 137:1022–1036CrossRefGoogle Scholar
  17. 17.
    Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE et al. for the MOCHA Investigators (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807–2816PubMedCrossRefGoogle Scholar
  18. 18.
    Gogia H, Mehra A, Parikh S, Raman M, Uppal JA, Johnson JV, Elkayam U (1995) Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 26:1575–1580PubMedCrossRefGoogle Scholar
  19. 19.
    Muenzel T, Kurz S, Rajagopalan S, Martin T, Berrington WR, Thompson JA, Fruman BA, Harrison DG (1996) Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. J Clin Invest 98:1465–1470CrossRefGoogle Scholar
  20. 20.
    Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourey LA, Jolly MK for the RADIANCE Study (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med 329:1–7PubMedCrossRefGoogle Scholar
  21. 21.
    The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533CrossRefGoogle Scholar
  22. 22.
    Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Di Bianco R, Zeldis SM, et al for the PROMISE Study Research Group (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325:1468–1475PubMedCrossRefGoogle Scholar
  23. 23.
    Rector TS, Tschumperlin LK, Kubo SH, Bank AJ, Francis GS, McDonald KM, Keeler CA, Silver MA (1995) Use of the Living with Heart Failure Questionnaire to ascertain patients’ perspectives on improvement in quality of life versus risk of drug-induced death. J Cardiol Failure 1:201–206CrossRefGoogle Scholar
  24. 24.
    CIBIS Investigators and Committees (1994) A Randomized Trial of Beta-Blockade in Heart Failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765–1773Google Scholar
  25. 25.
    Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL for the Prospective Randomized Amlodipine Survival Evaluation Study Group (1996) The effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335:1107–1114PubMedCrossRefGoogle Scholar
  26. 26.
    Doval HC, Nul DR, Grancelli H, Perrone SV, Bortman GR, Curiel R for Grupo de Estudio de la Sobrevida en la Insufficiencia Cardiaca en Argentina (GESICA) (1994) Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344:493–498PubMedCrossRefGoogle Scholar
  27. 27.
    Singh SN, Fletcher RD, Gross Fisher SG, et al. (1995) Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333:77–82PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1998

Authors and Affiliations

  • J. N. Cohn

There are no affiliations available

Personalised recommendations